Professor Michael Coleman University positionvan Geest Professor of Neuroscience Professor Michael Coleman is pleased to consider applications from prospective PhD students. DepartmentsDepartment of Clinical Neurosciences InstitutesBabraham Institute and Cambridge Centre for Brain Repair Home pagehttps://colemanlab.brc.cam.ac.uk (personal home page) Research ThemeInterestsWe study axon degeneration and its roles in neurodegenerative disease. One focus is proteins regulating the degeneration of injured axons (‘Wallerian degeneration'), which we have linked into a molecular pathway. Disease models involving similar mechanisms include several of peripheral neuropathies, Parkinson’s disease, glaucoma, motor neuron disease and multiple sclerosis. We aim to completely characterize the Wallerian pathway, identify human diseases associated with it and develop drugs to modify it. A second major interest is axonal pathology in Alzheimer’s disease. Using a new organotypic hippocampal slice culture model, we are studying the earliest pathogenic events in amyloid pathology and their dependence on Abeta and tau. We are collaborating on ALS, traumatic brain injury, neuropathic pain and white matter damage in Alzheimer’s disease. Finally, we have a developing interest in roles that rare axonal disease genes could play in axon survival in more common disorders.  14 day lesioned sciatic nerves from wild-type and WldS mice and rats, showing neuroprotective effect of the WldS gene View image full-size (2999x2249 pixels) Research Focus
EquipmentCalcium imaging Cell culture Confocal microscopy Fluorescence microscopy Immunohistochemistry Live imaging Microscopy Mouse genetics Protein purification Recombinant protein expression Collaborators
Associated News Items
Key publicationsColeman MP and Höke A (2020), “Programmed axon degeneration: from mouse to mechanism to medicine. ” Nat Rev Neurosci 21: 183-196 Huppke P, Wegener E, Gilley J, Angeletti C, Kurth I, Drenth JPH, Stadelmann C, Barrantes-Freer A, Brück W, Thiele H, Nürnberg P, Gärtner J, Orsomando G, Coleman MP (2019), “Homozygous NMNAT2 mutation in sisters with polyneuropathy and erythromelalgia. ” Exp Neurol. 320 Lukacs M*, Gilley J*, Zhu Y*, Orsomando G, Angeletti C, Liu J, Yang X, Park J, Hopkin RJ, Coleman MP, Zhai RG, Stottmann RW (2019), “Severe biallelic loss-of-function mutations in NMNAT2 in two fetuses with fetal akinesia deformation sequence. ” Exp Neurol. 320 White MA, Kim E, Duffy A, Adalbert R, Phillips BU, Peters OM, Stephenson J, Yang S, Massenzio F, Lin Z, Andrews S, Segonds-Pichon A, Metterville J, Saksida LM, Mead R, Ribchester RR, Barhomi Y, Serre T, Coleman MP, Fallon J, Bussey TJ, Brown Jr RH, Sreedharan J (2018), “TDP-43 gains function due to perturbed autoregulation in a Tardbp knock-in mouse model of ALS-FTD” Nat. Neurosci. 21(4):552-563 Gilley J, Ribchester RR, Coleman MP (2017), “Sarm1 deletion, but not WldS, confers lifelong rescue in a mouse model of severe axonopathy” Cell Reports 21(1):10-16 Harwell CS, Coleman MP (2016), “Synaptophysin depletion and intraneuronal A? in organotypic hippocampal slice cultures from huAPP transgenic mice” Mol Neurodegener 11(1):44 Gilley J, Orsomando G, Nascimento-Ferreira I, Hsueh Y-P, Coleman MP (2015), “Absence of SARM1 rescues development and survival of NMNAT2-deficient axons” Cell Reports 10: 1974-81 Conforti L, Gilley J, Coleman MP (2014), “Wallerian degeneration: an emerging axon death pathway linking injury and disease.” Nat Rev Neurosci 15(6):394-409 Details Osterloh JM, Yang J, Rooney TM, Fox AN, Adalbert R, Powell EH, Sheehan AE, Avery MA, Hackett R, Logan MA, MacDonald JM, Ziegenfuss JS, Milde S, Hou YJ, Nathan C, Ding A, Brown RH Jr, Conforti L, Coleman M, Tessier-Lavigne M, Züchner S, Freeman MR (2012), “dSarm/Sarm1 is required for activation of an injury-induced axon death pathway.” Science 337(6093):481-4 Details Coleman MP, Freeman MR (2010), “Wallerian degeneration, wld(s), and nmnat.” Annu Rev Neurosci 33:245-67 Details Gilley J, Coleman MP (2010), “Endogenous Nmnat2 is an essential survival factor for maintenance of healthy axons.” PLoS Biol 8(1):e1000300 Details Adalbert R, Nogradi A, Babetto E, Janeckova L, Walker SA, Kerschensteiner M, Misgeld T, Coleman MP (2009), “Severely dystrophic axons at amyloid plaques remain continuous and connected to viable cell bodies.” Brain 132(Pt 2):402-16 Details Beirowski B, Babetto E, Gilley J, Mazzola F, Conforti L, Janeckova L, Magni G, Ribchester RR, Coleman MP (2009), “Non-nuclear Wld(S) determines its neuroprotective efficacy for axons and synapses in vivo.” J Neurosci 29(3):653-68 Details Publicationsin pressAdemi M, Yang X, Coleman MP, Gilley, J (in press), “SARM1 alleles encoding loss-of-function variants occur naturally in the human population” Scientific Reports 2022Angeletti C, Amici A, Gilley J, Loreto A, Trapanotto AG, Antoniou C, Merlini E, Coleman, MP, Orsomando, G (2022), “SARM1 is a multi-functional NAD(P)ase with prominent base exchange activity, all regulated bymultiple physiologically relevant NAD metabolites” iScience 25: 103812 Coleman MP (2022), “Axon biology in ALS: mechanisms of axon degeneration and prospects for therapy” Neurotherapeutics Crawford CL, Antoniou C, Komarek L, Schultz V, Donald CL, Montague P, Barnett SC, Linington C, Willison HJ, Kohl A, Coleman MP, Edgar JM (2022), “SARM1 Depletion Slows Axon Degeneration in a CNS Model of Neurotropic Viral Infection ” Front Mol Neurosci. 15:860410 Merlini E, Coleman MP, Loreto A (2022), “Mitochondrial dysfunction as a trigger for programmed axon death” Trends Neurosci 45: 53-63 2021Arthur-Farraj P, Coleman MP (2021), “Lessons from injury: how nerve injury studies reveal basic biological mechanisms and therapeutic opportunities for peripheral nerve diseases” Neurotherapeutics 18: 2200-2221 Gilley J, Jackson O, Pipis M, Estiar MA, Al-Chalabi A, Danzi MC, van Eijk KR, Goutman SA, Harms MB, Houlden H, Iacoangeli A, Kaye J, Lima L; Queen Square Genomics, Ravits J, Rouleau GA, Schüle R, Xu J, Züchner S, Cooper-Knock J, Gan-Or Z, Reilly MM, Coleman MP (2021), “Enrichment of SARM1 alleles encoding variants with constitutively hyperactive NADase in patients with ALS and other motor nerve disorders.” Elife 10:e70905 Gould SA, Gilley J, Ling K, Jaffar-Nejad P, Ringo F, Coleman MP (2021), “Sarm1 Haploinsufficiency and Low Expression Levels after Antisense Oligonucleotides Delays Programmed Axon Degeneration” Cell Rep 37: 110108 Gould SA, White M, Wilbrey AL, Por E, Coleman MP, Adalbert R (2021), “Protection against oxaliplatin-induced mechanical and thermal hypersensitivity in Sarm1 -/- mice” Exp Neurol Apr;338:113607 Hopkins EL, Gu W, Kobe B, Coleman MP (2021), “A Novel NAD Signaling Mechanism in Axon Degeneration and its Relationship to Innate Immunity” Frontiers in Molecular Biosciences 8: 703532 Lin Z, Kim E, Ahmed M, Han G, Simmons C, Redhead Y, Bartlett J, Pena Altamira LE, Callaghan I, White MA, Singh N, Sawiak S, Spires-Jones T, Vernon AC, Coleman MP, Green J, Henstridge C, Davies JS, Cash D, Sreedharan J (2021), “MRI-guided histology of TDP-43 knock-in mice implicates parvalbumin interneuron loss, impaired neurogenesis and aberrant neurodevelopment in amyotrophic lateral sclerosis-frontotemporal dementia” Brain Commun 3(2):fcab114 Lin Z, Kim E, Ahmed M, Han G, Simmons C, Redhead Y, Bartlett J, Pena Altamira LE, Callaghan I, White MA, Singh N, Sawiak S, Spires-Jones T, Vernon AC, Coleman MP, Green J, Henstridge C, Davies JS, Cash D, Sreedharan J (2021), “MRI-guided histology of TDP-43 knock-in mice implicates parvalbumin interneuron loss, impaired neurogenesis and aberrant neurodevelopment in amyotrophic lateral sclerosis-frontotemporal dementia” Brain Commun 3(2):fcab114 Loreto A, Angeletti C, Gu W, Osborne A, Nieuwenhuis B, Gilley J, Merlini E, Arthur-Farraj P, Amici A, Luo Z, Hartley-Tassell L, Ve T, Desrochers LM, Wang Q, Kobe B, Orsomando G, Coleman MP (2021), “Neurotoxin-mediated potent activation of the axon degeneration regulator SARM1” Elife 10:e72823 2020Dembny P, Newman AG, Singh M, Hinz M, Szczepek M, Krüger C, Adalbert R, Dzaye O, Trimbuch T, Wallach T, Kleinau G, Derkow K, Richard BC, Schipke C, Scheidereit C, Stachelscheid H, Golenbock D, Peters O, Coleman M, Heppner FL, Scheerer P, Tarabykin V, Ruprecht K, Izsvák Z, Mayer J, Lehnardt S. (2020), “Human endogenous retrovirus HERV-K(HML-2) RNA causes neurodegeneration through Toll-like receptors” JCI Insight Durrant CS, Ruscher K, Sheppard O, Coleman MP* Özen I (2020), “Beta secretase 1-dependent amyloid precursor protein processing promotes excessive vascular sprouting through NOTCH3 signalling. ” Cell Death Dis 11: 98 Hill CS, Sreedharan J, Loreto A, Menon DK and Coleman MP (2020), “Loss of highwire protects against the deleterious effects of traumatic brain injury in drosophila melanogaster. ” Frontiers in Neurology Loreto A, Hill C, Hewitt VL, Orsomando G, Angeletti C, Gilley J, Lucci C, Sanchez-Martinez A, Whitworth AJ, Conforti L, Dajas-Bailador F, Coleman MP (2020), “Mitochondrial impairment activates the Wallerian pathway through depletion of NMNAT2 leading to SARM1-dependent axon degeneration. ” Neurobiol Dis 134 Mabbitt PD, Loreto A, Dery MA, Fletcher AJ, Stanley M, Pao KC, Wood NT, Coleman MP, Virdee S (2020), “Structural basis for RING-Cys-relay E3 ligase activity and its role in axon integrity. ” Nat Chem Biol 2019Adalbert R, Kaieda A, Antoniou C, Loreto A, Yang X, Gilley J, Hoshino T, Uga K, Makhija M, Coleman MP (2019), “Novel HDAC6 inhibitors increase tubulin acetylation and rescue axonal transport of mitochondria in a model of Charcot-Marie-Tooth Type 2F. ” ACS Chem Neurosci 11: 258-267 Horsefield, S., Burdett, H., Zhang, X., Manik, M., Shi, Y., Chen, J., Qi, T., Gilley, J., Lai, J., Rank, M., Casey, L., Gu, W., Ericsson, D., Foley, G., Hughes, R. Bosanac, T., von Itztein, M., Rathjen, J., Nanson, J., Boden M, Dry I, Williams S, Staskawicz B, Coleman MP, Ve T, Dodds P*, Kobe B* (2019), “Structural basis of NAD+-cleavage activity by animal and plant TIR domains with functions in cell-death pathways. ” Science 365:793-799 Sheppard O, Coleman MP, and Durrant CS (2019), “Lipopolysaccharide-induced neuroinflammation induces presynaptic disruption through a direct action on brain tissue involving microglia-derived interleukin 1 beta. ” Journal of Neuroinflammation 16(106) White, M., Lin, Z., Kim, E., Henstridge, C., Altamira, E., Hunt, C., Burchill E, Callaghan I, Loreto A, Brown-Write H, Mead R, Simmons C, Cash D, Coleman MP, Sreedharan J (2019), “Sarm1 deletion suppresses TDP-43-linked motor neuron degeneration and cortical spine loss. ” Acta Neuropathologica Communications 7: 166 2018Adalbert R, Milde S, Durrant C, Ando K, Stygelbout V, Yilmaz Z, Gould S, Brion JP, Coleman MP (2018), “Interaction between a MAPT variant causing frontotemporal dementia and mutant APP affects axonal transport” Neurobiol Aging. 68:68-75 Carpi FM, Cortese M, Orsomando G, Polzonetti V, Vincenzetti S, Moreschini B, Coleman MP, Magni G, Pucciarelli S (2018), “Simultaneous quantification of nicotinamide mononucleotide and related pyridine compounds in mouse tissues by UHPLC-MS/MS” Sep Sci plus. 1(1):22-30 Fricker M, Tolkovsky AM, Borutaite V, Coleman MP, Brown GC (2018), “Neuronal cell death” Physiological Reviews 98(2):813-880 Gilley J, Mayer P, Yu G, Coleman MP (2018), “Low levels of NMNAT2 compromise axon development and survival” Human Molecular Genetics Hill CS, Menon DK, and Coleman MP (2018), “P7C3-A20 neuroprotection is independent of Wallerian degeneration in Primary Neuronal Culture. ” NeuroReport 29: 1544-49 2017Di Stefano M, Loreto A, Orsomando G, Mori V, Zamporlini F, Hulse RP, Webster J, Donaldson LF, Gering M, Raffaelli N, Coleman MP, Gilley J, Conforti L (2017), “NMN deamidase robustly delays Wallerian degeneration and rescues axonal defects caused by NMNAT2 deficiency in vivo” Curr Biol 27(6):784-794 2016Clark DE, Waszkowycz B, Wong M, Lockey PM, Adalbert R, Gilley J, Clark J, Coleman MP (2016), “Application of virtual screening to the discovery of novel nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with potential for the treatment of cancer and axonopathies” Bioorg Med Chem Lett 26(12):2920-6 Gilley J, Ando K, Seereeram A, Rodriguez-Martin T, Pooler AM, Sturdee L, Anderton BH, Brion JP, Hanger DP, Coleman MP (2016), “Mislocalization of neuronal tau in the absence of tangle pathology in phosphomutant tau knockin mice” Neurobiol Aging 39:1-18 Hill CS, Coleman MP, Menon, DK (2016), “Traumatic Axonal Injury: Mechanisms and Translational Opportunities” Trends Neurosci 39(5):311-24 Hung CO, Coleman MP (2016), “KIF1A mediates axonal transport of BACE1 and identification of independently moving cargoes in living SCG neurons” Traffic Rodriguez-Martin T, Pooler AM, Morotz G, de Vos K, Gilley J, Coleman MP, Hanger DP (2016), “Axonal mitochondrial number is reduced in neurons of mice expressing the P301L tau mutation associated with frontotemporal dementia” Neurobiol Dis 85:1-10 2015Di Stefano M, Nascimento-Ferreira I, Orsomando G, Mori V, Gilley J, Brown R, Janeckova L, Vargas ME, Worrell LA, Loreto A, Tickle J, Patrick J, Webster JR, Marangoni M, Carpi FM, Pucciarelli S, Rossi F, Meng W, Sagasti A, Ribchester RR, Magni G, Coleman MP, Conforti L (2015), “A rise in NAD precursor nicotinamide mononucleotide (NMN) after injury promotes axon degeneration” Cell Death Diff 22:731-42 Munidinger TO, Cooper E, Coleman MP, Taborsky GJ (2015), “Short-term diabetic hyperglycemia suppresses celiac ganglia neurotransmission thereby impairing sympathetically-mediated glucagon responses” Am J Physiol 309:E246-55 2014Godzik K, Coleman MP (2014), “The axon protective WldS protein partially rescues mitochondrial respiration and glycolysis after axonal injury” J Mol Neurosci 55: 865-71 Marangoni M, Adalbert R, Janeckova L, Patrick J, Kohli J, Coleman MP, Conforti L (2014), “Age-related axonal swellings precede other neuropathological hallmarks in a knock-in mouse model of Huntington's disease.” Neurobiol Aging 35(10):2382-93 Details Milde S, Adalbert R, Elaman H, Coleman MP (2014), “Axonal transport declines in two phases during growth and in old age but remains stable throughout adult life” Neurobiol Aging 36:971-81 Milde S, Coleman MP (2014), “Identification of palmitoyltransferase and thioesterase enzymes that control the subcellular localisation of axon survival factor Nmnat2” J Biol Chem 289:32858-70 2013Coleman MP (2013), “The challenges of axon survival: introduction to the special issue on axonal degeneration.” Exp Neurol 246:1-5 Details Evans C, Cook SJ, Coleman MP, Gilley J (2013), “MEK inhibitor U0126 reverses protection of axons from Wallerian degeneration independently of MEK-ERK signaling.” PLoS One 8(10):e76505 Details Gilley J, Adalbert R, Yu G, Coleman MP (2013), “Rescue of peripheral and CNS axon defects in mice lacking NMNAT2.” J Neurosci 33(33):13410-24 Details Milde S, Fox AN, Freeman MR, Coleman MP (2013), “Deletions within its subcellular targeting domain enhance the axon protective capacity of Nmnat2 in vivo.” Sci Rep 3:2567 Details Milde S, Gilley J, Coleman MP (2013), “Axonal trafficking of NMNAT2 and its roles in axon growth and survival in vivo.” Bioarchitecture 3(5):133-140 Details Milde S, Gilley J, Coleman MP (2013), “Subcellular localization determines the stability and axon protective capacity of axon survival factor Nmnat2.” PLoS Biol 11(4):e1001539 Details Yang Y, Coleman M, Zhang L, Zheng X, Yue Z (2013), “Autophagy in axonal and dendritic degeneration.” Trends Neurosci 36(7):418-28 Details 2012Adalbert R, Coleman MP (2012), “Axon pathology in age-related neurodegenerative disorders.” Neuropathol Appl Neurobiol Details Adalbert R, Morreale G, Paizs M, Conforti L, Walker SA, Roderick HL, Bootman MD, Siklós L, Coleman MP (2012), “Intra-axonal calcium changes after axotomy in wild-type and slow Wallerian degeneration axons.” Neuroscience 225:44-54 Details Court FA, Coleman MP (2012), “Mitochondria as a central sensor for axonal degenerative stimuli.” Trends Neurosci 35(6):364-72 Details Gilley J, Seereeram A, Ando K, Mosely S, Andrews S, Kerschensteiner M, Misgeld T, Brion JP, Anderton B, Hanger DP, Coleman MP (2012), “Age-dependent axonal transport and locomotor changes and tau hypophosphorylation in a "P301L" tau knockin mouse.” Neurobiol Aging 33(3):621.e1-621.e15 Details Orsomando G, Cialabrini L, Amici A, Mazzola F, Ruggieri S, Conforti L, Janeckova L, Coleman MP, Magni G (2012), “Simultaneous single-sample determination of NMNAT isozyme activities in mouse tissues.” PLoS One 7(12):e53271 Details 2011Coleman M (2011), “Molecular signaling how do axons die?” Adv Genet 73:185-217 Details Conforti L, Janeckova L, Wagner D, Mazzola F, Cialabrini L, Di Stefano M, Orsomando G, Magni G, Bendotti C, Smyth N, Coleman M (2011), “Reducing expression of NAD+ synthesizing enzyme NMNAT1 does not affect the rate of Wallerian degeneration.” FEBS J 278(15):2666-79 Details Gilley J, Adalbert R, Coleman MP (2011), “Modelling early responses to neurodegenerative mutations in mice.” Biochem Soc Trans 39(4):933-8 Details Meyer zu Horste G, Miesbach TA, Muller JI, Fledrich R, Stassart RM, Kieseier BC, Coleman MP, Sereda MW (2011), “The Wlds transgene reduces axon loss in a Charcot-Marie-Tooth disease 1A rat model and nicotinamide delays post-traumatic axonal degeneration.” Neurobiol Dis 42(1):1-8 Details 2010Andrews S, Gilley J, Coleman MP (2010), “Difference Tracker: ImageJ plugins for fully automated analysis of multiple axonal transport parameters.” J Neurosci Methods 193(2):281-7 Details Babetto E, Beirowski B, Janeckova L, Brown R, Gilley J, Thomson D, Ribchester RR, Coleman MP (2010), “Targeting NMNAT1 to axons and synapses transforms its neuroprotective potency in vivo.” J Neurosci 30(40):13291-304 Details Beirowski B, Morreale G, Conforti L, Mazzola F, Di Stefano M, Wilbrey A, Babetto E, Janeckova L, Magni G, Coleman MP (2010), “WldS can delay Wallerian degeneration in mice when interaction with valosin-containing protein is weakened.” Neuroscience 166(1):201-11 Details Beirowski B, Nógrádi A, Babetto E, Garcia-Alias G, Coleman MP (2010), “Mechanisms of axonal spheroid formation in central nervous system Wallerian degeneration.” J Neuropathol Exp Neurol 69(5):455-72 Details 2009Bridge KE, Berg N, Adalbert R, Babetto E, Dias T, Spillantini MG, Ribchester RR, Coleman MP (2009), “Late onset distal axonal swelling in YFP-H transgenic mice.” Neurobiol Aging 30(2):309-21 Details Conforti L, Wilbrey A, Morreale G, Janeckova L, Beirowski B, Adalbert R, Mazzola F, Di Stefano M, Hartley R, Babetto E, Smith T, Gilley J, Billington RA, Genazzani AA, Ribchester RR, Magni G, Coleman M (2009), “Wld S protein requires Nmnat activity and a short N-terminal sequence to protect axons in mice.” J Cell Biol 184(4):491-500 Details Morreale G, Conforti L, Coadwell J, Wilbrey AL, Coleman MP (2009), “Evolutionary divergence of valosin-containing protein/cell division cycle protein 48 binding interactions among endoplasmic reticulum-associated degradation proteins.” FEBS J 276(5):1208-20 Details Wong F, Fan L, Wells S, Hartley R, Mackenzie FE, Oyebode O, Brown R, Thomson D, Coleman MP, Blanco G, Ribchester RR (2009), “Axonal and neuromuscular synaptic phenotypes in Wld(S), SOD1(G93A) and ostes mutant mice identified by fiber-optic confocal microendoscopy.” Mol Cell Neurosci 42(4):296-307 Details 2008Beirowski B, Babetto E, Coleman MP, Martin KR (2008), “The WldS gene delays axonal but not somatic degeneration in a rat glaucoma model.” Eur J Neurosci 28(6):1166-79 Details Wilbrey AL, Haley JE, Wishart TM, Conforti L, Morreale G, Beirowski B, Babetto E, Adalbert R, Gillingwater TH, Smith T, Wyllie DJ, Ribchester RR, Coleman MP (2008), “VCP binding influences intracellular distribution of the slow Wallerian degeneration protein, Wld(S).” Mol Cell Neurosci 38(3):325-40 Details 2007Adalbert R, Gilley J, Coleman MP (2007), “Abeta, tau and ApoE4 in Alzheimer's disease: the axonal connection.” Trends Mol Med 13(4):135-42 Details Conforti L, Adalbert R, Coleman MP (2007), “Neuronal death: where does the end begin?” Trends Neurosci 30(4):159-66 Details Conforti L, Fang G, Beirowski B, Wang MS, Sorci L, Asress S, Adalbert R, Silva A, Bridge K, Huang XP, Magni G, Glass JD, Coleman MP (2007), “NAD(+) and axon degeneration revisited: Nmnat1 cannot substitute for Wld(S) to delay Wallerian degeneration.” Cell Death Differ 14(1):116-27 Details Wishart TM, Macdonald SH, Chen PE, Shipston MJ, Coleman MP, Gillingwater TH, Ribchester RR (2007), “Design of a novel quantitative PCR (QPCR)-based protocol for genotyping mice carrying the neuroprotective Wallerian degeneration slow (Wlds) gene.” Mol Neurodegener 2:21 Details 2006Adalbert R, Nógrádi A, Szabó A, Coleman MP (2006), “The slow Wallerian degeneration gene in vivo protects motor axons but not their cell bodies after avulsion and neonatal axotomy.” Eur J Neurosci 24(8):2163-8 Details Gillingwater TH, Wishart TM, Chen PE, Haley JE, Robertson K, MacDonald SH, Middleton S, Wawrowski K, Shipston MJ, Melmed S, Wyllie DJ, Skehel PA, Coleman MP, Ribchester RR (2006), “The neuroprotective WldS gene regulates expression of PTTG1 and erythroid differentiation regulator 1-like gene in mice and human cells.” Hum Mol Genet 15(4):625-35 Details Laser H, Conforti L, Morreale G, Mack TG, Heyer M, Haley JE, Wishart TM, Beirowski B, Walker SA, Haase G, Celik A, Adalbert R, Wagner D, Grumme D, Ribchester RR, Plomann M, Coleman MP (2006), “The slow Wallerian degeneration protein, WldS, binds directly to VCP/p97 and partially redistributes it within the nucleus.” Mol Biol Cell 17(3):1075-84 Details |
